Results for tag: "Emend"

The Emend market is a subset of the Gastrointestinal Drugs market, focusing on drugs used to treat nausea and vomiting caused by chemotherapy and radiation therapy. Emend is a brand name for the drug aprepitant, which is a neurokinin-1 receptor antagonist. It is used to prevent nausea and vomiting in patients undergoing chemotherapy or radiation therapy. It is also used to treat nausea and vomiting caused by certain medications. Emend is available in both oral and intravenous formulations. The Emend market is highly competitive, with several companies offering similar products. Some of the major players in the market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, and Novartis AG. Show Less Read more